1. Cosgrove SE, Carmeli Y. The impact of antimicrobial resistance on health and economic outcomes. Clin Infect Dis 2003;36:1433–1437PMID : 12766839.
2. Chow JW, Fine MJ, Schlaes DM, et al. Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med 1991;115:585–590PMID : 1892329.
3. Holmberg SD, Solomon SL, Blake PA. Health and economic impacts of antimicrobial resistance. Rev Infect Dis 1987;9:1065–1078PMID : 3321356.
4. Phelps CE. Bug/drug resistance: sometimes less is more. Med Care 1989;27:194–203PMID : 2918766.
5. Chong Y, Lee K. Present situation of antimicrobial resistance in Korea. J Infect Chemother 2000;6:189–195PMID : 11810564.
6. Kim JM, Lee Y, Ahn H, Kim NJ, Kang MY, Hong SA. National survey of prescribing patterns and usage analysis of antibiotics in Korea. J Korean Soc Chemother 2001;19:105–195.
7. Rheem I, Pai H, Choi E, Oh T, Choi DO, Park WS. Usage analysis of surgical prophlaxis of cephalosporins and aminoglycosides in a university hospital. Infect Chemother 2004;36:24–31.
8. Kim JY, Bae S, Hong K, La H. Drug use evaluation on ceftriaxone. J Korean Soc Hosp Pharm 1999;16:48–51.
9. Yeun ES, Park JW, Kim SJ, Jang HK, Kim ON. Drug use evaluatioin of ciprofloxacin. J Korean Soc Hosp Pharm 1999;16:60–70.
10. KIm SH, Bae SM, Hong KJ, La HO, Kang MY. Drug use evaluation on vancomycin. J Korean Soc Hosp Pharm 1998;15:509–512.
11. Kim MS, Choi KE, Lee SH. Drug use evaluation of imipenem/cilastatin. J Korean Soc Hosp Pharm 2002;19:413–421.
12. Sesin GP, Gannon PM. Ceftriaxone drug utilization evaluation in a large community hospital. DICP 1991;25:872–873PMID : 1949954.
13. American Society of Hospital Pharmacist. Criteria for Drug use Evaluation. 1993;Vol. 4:Bethesda: American Society of Hospital Pharmacist.